HomeMOLN • NASDAQ
add
Molecular Partners AG
Previous close
$6.78
Day range
$6.23 - $7.60
Year range
$3.32 - $12.70
Market cap
234.39M USD
Avg Volume
20.79K
In the news
Financials
Income Statement
Revenue
Net income
| (CHF) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 1.55M | 273.73% |
Operating expense | 4.44M | -4.84% |
Net income | -15.08M | 5.66% |
Net profit margin | -972.40 | 74.76% |
Earnings per share | — | — |
EBITDA | -15.37M | -0.62% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (CHF) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 159.13M | -27.07% |
Total assets | 170.62M | -25.98% |
Total liabilities | 15.05M | -38.62% |
Total equity | 155.57M | — |
Shares outstanding | 33.18M | — |
Price to book | 1.45 | — |
Return on assets | -22.42% | — |
Return on capital | -24.17% | — |
Cash Flow
Net change in cash
| (CHF) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -15.08M | 5.66% |
Cash from operations | -15.72M | -18.38% |
Cash from investing | 13.15M | 225.87% |
Cash from financing | -267.00K | 2.55% |
Net change in cash | -2.66M | 75.12% |
Free cash flow | -9.80M | -15.75% |
About
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Founded
2004
Website
Employees
162
